NCT01422915

Sorbent Therapy of the Cutaneous Porphyrias

• Status: Completed
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 4 (actual)
• Sponsor: Brigham and Women's Hospital · Academic / Other
• Sex: All
• Age: 22 Years – 60 Years
• Healthy volunteers: Accepted

Summary

The investigators demonstrated that cholestyramine is an effective binding agent in vitro for porphyrins. A few isolated case reports of treatment of individuals with a cutaneous porphyria suggest that cholestyramine and colestipol effectively remove porphyrins. Hypothesis: orally administered colestipol will effectively reduce sun sensitivity and lower erythrocyte porphyrin concentrations in subjects with erythropoietic protoporphyria (EPP).

Detailed description

Four adults with proven EPP volunteered as subjects for this study. First period: Subjects received 1 gm colestipol twice daily for \~45 days, then 2 gm twice daily for \~45 days. Labs included CBC; liver chemistries including cholesterol; serum iron, TIBC and ferritin; erythrocyte and plasma protoporphyrin concentrations; and completion of sun exposure questionnaire focused on cutaneous manifestations every 2-4 weeks. Second period: Subjects received colestipol tablets, 2 grams twice daily, completing the sun exposure questionnaire and protoporphyrin determinations \~monthly for 5-6 months.

Conditions

• Erythropoietic Protoporphyria

Interventions

Type	Name	Description
DRUG	Colestipol	2 grams morning and bedtime for 90 days.

Timeline

• Start date: 2011-05-01
• Primary completion: 2012-03-01
• Completion: 2012-03-01
• First posted: 2011-08-25
• Last updated: 2017-04-25
• Results posted: 2017-04-25

Locations

1 site across 1 country: United States